VacCan · Development of new multi-valent vaccine systems against Candida pathogens
„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“
- Период
- 2021-07-01 → 2023-08-14
- Финансиране от ЕС
- 212 934 €
- Участници
- 1
- Схема
- MSCA-IF
Линиите свързват координатора с партньорите.
Накратко на български
Разработват се нови ваксини срещу гъбички от вида Candida albicans, които причиняват повърхностни и тежки системни инфекции. Това е важно, защото в момента няма лицензирани ваксини, а смъртността при пациенти с отслабен имунитет е много висока.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
Development of new multi-valent vaccine systems against Candida pathogens
Fungal infections kill an estimated 1.5 million people each year, four times greater than the global mortality due to malaria or breast cancer. The fungal pathogen Candida albicans is the most pathogenic of the Candida species and causes millions of superficial mucosal infections and approximately 200,000 deaths per annum due to invasive and disseminated disease in susceptible patient populations. Fungal infections in immunocompromised patients have an unacceptably high mortality rate of approximately 40%, and the yearly healthcare expenditure for the treatment of fungal diseases is estimated to be $15 billion. The clinical treatment of fungal diseases is hampered by poor and time-consuming diagnostics, a limited repertoire of anti-fungal drugs, and increasing levels of resistance to anti-fungal prophylaxis. Crucially, there are currently no licensed vaccines against fungal pathogen. This represents a clear opportunity in global healthcare provision. The principal objective of this project was developing a new vaccine candidate to Candida albicans, the leading cause of fungal infection in humans worldwide.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
The fungal pathogen Candida albicans is the most pathogenic of the Candida species and causes millions of superficial mucosal infections and approximately 200,000 deaths per annum due to invasive and disseminated disease in susceptible patient populations. Fungal infections in immunocompromised patients have an unacceptably high mortality rate of approximately 40%, and the yearly healthcare expenditure for the treatment of fungal diseases is estimated to be $15 billion. The clinical treatment of fungal diseases is hampered by poor and time-consuming diagnostics, a limited repertoire of anti-fungal drugs, and increasing levels of resistance to anti-fungal prophylaxis. Crucially, there are currently no licensed vaccines against fungal pathogen. Recent attempts to formulate vaccines have involved delivering simple mixtures of peptide/protein components of the target fungi with adjuvants (without controlled chemical conjugation), and without specific synthetic control have met with limited success. This project will develop new vaccine candidates to Candida albicans, the leading cause of fungal infection in humans worldwide. Unlike previous efforts, a multi-valent approach will be employed, chemically coupling three proteins expressed by Candida albicans. This synthetic approach will ensure the concurrent delivery of multiple protein antigens to overcome barriers faced by previous attempts at developing vaccines. Specifically, the project will focus on the synthesis of multi-valent systems by conjugating proteins to the surface of either: i) dendrimeric scaffolds (3D nanoscale covalent structures) or ii) liposomes (3D nanoscale self-assembled structures). This multidisciplinary proposal will use cutting-edge methodologies to address an unmet clinical need in fungal immunology that will deliver exceptional value through innovative vaccine research against fungal pathogens that are an escalating threat to global health.
Оригинален текст от CORDIS (на английски).
Участници
- KING'S COLLEGE LONDON · LondonКоординаторОбединеното кралство
Връзки
Данни: CORDIS, © Европейски съюз